Teva to keep propofol out of death-row prisons; GW, Almirall may yank Sativex in Germany on lowball price; GlaxoSmithKline, Intermune win NICE nods for Revolade, Esbriet;

@FiercePharma: Novartis CEO Joe Jimenez's latest interview with a big media outlet. How $NVS forges ahead, from CNN. Report | Follow @FiercePharma

@EricPFierce: Canada's Apotex, already in NAFTA fight with US over 2009 FDA import ban, finds itself back in the FDA doghouse. Article | Follow @EricPFierce

> Teva Pharmaceutical Industries ($TEVA) says it will resume manufacturing the anesthetic propofol and will control distribution to prevent its use by prisons in executions. Report

> GW Pharmaceuticals and its partner Almirall may stop selling their Sativex drug for multiple sclerosis patients in Germany after officials there set a price "significantly lower" than that in other European countries. Report

> GlaxoSmithKline's ($GSK) Revolade won a thumbs-up from the National Institute for Health and Clinical Excellence, as a treatment for chronic immune thrombocytopenic purpura. Report

> Teva Pharmaceutical Industries chose former Dyax executive Ivana Magovcevic-Liebisch to be its SVP and head of business development, a newly created post. Release | Release

> InterMune's ($ITMN) lung drug Esbriet won a recommendation from NICE as a treatment for idiopathic pulmonary fibrosis. Report

> Germany's generics maker Stada posted a 7% increase in 2012 sales of €1.84 billion ($2.4 billion); profits grew fourfold on cost-cutting and some one-time gains. Release

Medical Device News

 @FierceMedDev: More worry for Intuitive as MA questions robotic surgery. Item | Follow @FierceMedDev

 @MarkHFierce: Our latest special report: Med Tech's 2012 R&D big spenders. Who made the list? Feature | Follow @MarkHFierce

 @DamianFierce: A House Dem has taken up the medical device tax repeal cause, introducing a bill to kill the charge. Report | Follow @DamianFierce

> St. Jude claims "landmark study" quells concerns over heart-plug benefits. Article

> Abbott's MitraClip draws mixed vote from FDA panel. News

> Swiss develop multitasking, implantable Dx chip. More

Biotech News

 @FierceBiotech: From FierceBiotechResearch.com: New database a boon for genomics research. Story | Follow @FierceBiotech

@JohnCFierce: Moderna will now triple its staff in Cambridge, MA, if you're looking for a job. Article | Follow @JohnCFierce

@RyanMFierce: Celgene makes big splash in gene therapy with two cancer collaborations. News | Follow @RyanMFierce

> Teva touts fresh PhIII evidence of oral MS drug's potential. News

> Enanta prices IPO shares at low end of range. Item

> GlaxoSmithKline reports another batch of weak results for malaria jab. Story

> Gene therapy combats acute leukemia in small study. More

Pharma Manufacturing News

> Teva returns to market with propofol. Story

> India has plan to meet Europe's new API regs. Report

> Sanofi again having manufacturing issues involving TB drug. Article

> FDA again on Apotex's case for plant problems. More

Vaccines News

> Flexible flu threatens pandemic preparedness. Report

> Anthrax vax vexes bioethics committee. Story

> U.K. smallpox rethink prompts stockpiling criticisms. Article

> Struggle against HPV vaccine skepticism intensifying. More

And Finally... Norovirus in U.S. children causes more than 1 million doctor visits each year at a cost of some $273 million. Report

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.